MacroGenics Initiates Phase 1 Study of MGD010 for the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MacroGenics Initiates Phase 1 Study of MGD010 for the Treatment of Autoimmune Disorders

ROCKVILLE, Md., March 16, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the initiation of a Phase 1 study with MGD010, its first Dual-Affinity Re-Targeting (DART®) molecule being developed for patients with autoimmune disorders.  MGD010 is a bi-specific molecule that simultaneously targets CD32B and CD79B, two B-cell surface proteins, for the treatment of autoimmune disorders.  MGD010 is designed to inhibit B-cell activation by exploiting the inhibitory function of CD32B, a checkpoint molecule expressed by B cells.  As a result of the study initiation, MacroGenics will receive a $3 million milestone payment from its partner, Takeda Pharmaceutical Company Limited.

"The initiation of this Phase 1 study marks the advancement of our third DART program into clinical development," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "MGD010 has been shown to inhibit B-cell activation by a novel dual-targeting mechanism without depleting B cells in pre-clinical models. We believe this molecule has the potential to address features that limit currently approved B-cell-targeted therapies, including delayed onset of action and prolonged depletion of antibody-producing B cells and thus, potentially treat a broader population of patients with autoimmune disorders."

The recently-initiated Phase 1 clinical trial is a first-in-human, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MGD010 in healthy subjects.

About the MGD010 Collaboration with Takeda

In May 2014, MacroGenics entered into an option agreement for the development and commercialization of MGD010 with Takeda Pharmaceutical Company Limited.  Takeda has an option to obtain an exclusive worldwide license for MGD010 following the completion of the Phase 1 study.  If Takeda exercises its option, it will assume responsibility for future development and pay MacroGenics an option exercise fee of $15 million. Assuming successful development and commercialization of MGD010, MacroGenics could receive up to an additional $468.5 million in clinical, regulatory and commercialization milestone payments. If commercialized, MacroGenics would receive double-digit royalties on any global net sales and has the option to co-promote MGD010 with Takeda in the United States.  Finally, MacroGenics may elect to fund a portion of Phase 3 clinical development in exchange for a North American profit share.

About MGD010

MGD010 is a humanized DART compound that simultaneously targets CD32B and CD79B.  In pre-clinical studies, MGD010 was shown to modulate the function of human B cells without B-cell depletion. In normal conditions, B cells utilize CD32B as one of the key negative regulators to ensure that tolerance to self is maintained and autoimmune disease does not occur. MGD010 exploits this mechanism and triggers this inhibitory "immune checkpoint" loop for the inhibition of B-cell function, an approach that may be useful for the treatment of patients with autoimmune disorders. MacroGenics believes this molecule preferentially blocks those B cells that are activated to produce the pathogenic antibodies that promote the autoimmune process. MGD010 was shown to inhibit B lymphocytes from SLE (Systemic Lupus Erythematosus) patients in vitro; furthermore, MGD010 inhibits the onset of autoimmunity in humanized mouse models. In a non-human primate study, MGD010 has demonstrated a favorable safety profile and pharmacological effect on targeted B cells in the absence of B-cell depletion.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which are designed to improve upon the performance of monoclonal antibodies and antibody-derived molecules. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.  Additional information about MacroGenics can be found on its corporate website at www.MacroGenics.com .  MacroGenics and DART are registered trademarks of MacroGenics, Inc.

MacroGenics' Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for MacroGenics, including statements about the company's strategy, future operations, clinical development of the company's therapeutic candidates, milestone or opt-in payments from the company's collaborators, the company's anticipated milestones and future expectations and plans and prospects for the company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the company's product candidates and other risk factors described in the company's filings with the Securities and Exchange Commission, including those discussed in the "Risk Factors" section of the company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission and any subsequent Quarterly Reports on Form 10-Q. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof. MacroGenics anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date hereof.

Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, Karen Sharma, Vice President MacDougall Biomedical Communications 1-781-235-3060,

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
Childcare Scale Makes Its Case, With Caveats Attached

Updated Category News Views 58

Childcare’s math is brutal before anybody starts arguing over ownership. Families need dependable hours, educators deserve better pay, and operators must keep buildings safe, staffed and open without pricing working parents clean out of the market. That is why this new Tyton Partners review of multi-site providers deserves a fair look, even if nobody should mistake a...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 77

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 66

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 268

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading

Top 5 Most Recently Viewed Articles

Freddie Mac's 30-Year Mortgage Rate Decreases Slightly

Updated Category News Views 219

Freddie Mac Reports on Mortgage Rates In recent reports from Freddie Mac, there's good news for potential homebuyers. The 30-year fixed-rate mortgage (FRM) has seen a slight decline, which is a welcome change in a fluctuating market. This current value sits at an average of 6.64%, reflecting a small drop from the previous week's average of 6.65%. Understanding the Current...

Continue Reading
Sports.com Partners with SEGG Media for Soccerex Event

Updated Category News Views 251

Sports.com Joins SEGG Media as Title Sponsor at Soccerex Miami 2025 MIAMI BEACH, Fla. — SEGG Media Corporation (NASDAQ: SEGG, LTRYW) has officially announced that Sports.com will take on the role of Title Sponsor for the engaging Soccerex Miami event happening at the Miami Beach Convention Center. This sponsorship reflects a significant commitment to promoting...

Continue Reading
Gastech 2025: A Global Convergence for Energy Innovations

Updated Category News Views 249

Gastech 2025 Unites the World of Energy Innovation Gastech 2025 welcomes more than 50,000 attendees from over 150 countries, establishing Milan as the global center for critical dialogues on energy supply, transformation, and innovation. This event has become a vital platform for high-level conversations that shape the future of energy. Leadership at Gastech 2025...

Continue Reading
Baird Confirms Outperform Rating for Costco Amidst Strong Growth

Updated Category News Views 68

Strong Sales Performance Driving Costco's Success Baird has reaffirmed its Outperform rating for Costco Wholesale (NASDAQ: COST), while upholding a price target of $975. The firm's latest insights indicate that Costco's global core comparable sales, excluding gas and foreign exchange influences, have surged by 8.9%. Such a rise is significant and demonstrates the...

Continue Reading
Celebrating a Decade of DNBSEQ™: Innovations and Impact

Updated Category News Views 290

Celebrating a Decade of DNBSEQ™ Technology MGI Tech Co., Ltd. (NASDAQ: MGI) is thrilled to celebrate ten years of its revolutionary DNBSEQ™ sequencing technology. This milestone marks a significant journey in transforming the landscape of genomics, offering solutions that not only enhance scientific research but also make genomic information more accessible to a...

Continue Reading